First patient dosed in Ph II trials of IBI310 and Tyvyt®

Dec 11, 2020

Innovent announces the first patient has been dosed in its Ph II trials of IBI310 (anti CTLA-4 monoclonal antibody) in combination with Tyvyt® (sintilimab) for the treatment of second-line or above advanced cervical cancer.

Print Page Mail Article